Evaluation of Optical Genome Mapping in Phi Negative Myeloproliferative Neoplasia in the Detection of Acquired Cytogenetic Abnormalities

Recruiting now · Not applicable

Conditions studied: Myeloproliferative Neoplasm, Optical Genome Mapping, Cytogenetics, Clonality, Prognostic Stratification

In brief

Standard cytogenetics (CBA +/- FISH) is of diagnostic and prognostic interest in Ph- MPN. However, its value is limited by the low frequency of detected abnormalities. The development of tools to increase the sensitivity of detection of chromosomal alterations is therefore particularly adapted to these pathologies. Optical genome mapping (OGM) is a high resolution "long read" technique that allows the identification of structural and copy number variations at the whole genome level. Several recent studies suggest that OGM is a future tool for cytogenetic characterization of haematological disorders. Its ability to describe structural abnormalities, including balanced ones, represents a major advantage over currently used technologies. Thus, OGM seems to be the key tool for cytogenetics of haematological malignancies in the coming years, making it possible to replace, under certain conditions, not only karyotype and FISH, but CMA and even RT-MLPA for the search for fusion transcripts, thus filling in the gaps in these techniques while maintaining their advantages. To define the place of this technology in Ph- MPN, the investigators will perform a OGM analysis on patients with Ph-MPN for whom bone marrow exploration is scheduled. These results will be compared with those of standard cytogenetics (CBA +/- FISH).

Key facts

Study ID

NCT05714592

Run by

Centre Hospitalier Universitaire, Amiens

People needed

300

Starts

2023-05-17

Expected to finish

2027-05-18

Last updated by the study team

2026-05-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patient 18 years of age or older
• Diagnosis or follow-up of polycythemia vera, essential thrombocythemia or primary or secondary myelofibrosis
• Requires bone marrow cytogenetics at diagnosis or follow-up
• Understanding of the French language
• Information of the patient and collection of no objection
• Person affiliated to a social security regime

You may not qualify if…

• Patient with BCR::ABL positive myeloproliferative neoplasia.
• Person with a medical history that may impair the ability to understand the information notice

Where it is running

• Centre Hospitalier Universitaire d'Amiens — Amiens, Picardie, France (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.